1. Genetics and Genomics

Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors

  1. Joseph M Replogle
  2. Jessica L Bonnar
  3. Angela N Pogson
  4. Christina R Liem
  5. Nolan K Maier
  6. Yufang Ding
  7. Baylee J Russell
  8. Xingren Wang
  9. Kun Leng
  10. Alina Guna
  11. Thomas M Norman
  12. Ryan A Pak
  13. Daniel M Ramos
  14. Michael Emmerson Ward
  15. Luke A Gilbert
  16. Martin Kampmann
  17. Jonathan S Weissman  Is a corresponding author
  18. Marco Jost  Is a corresponding author
  1. University of California, San Francisco, United States
  2. Whitehead Institute for Biomedical Research, United States
  3. Harvard Medical School, United States
  4. National Institutes of Health, United States
  5. National Institute of Neurological Disorders and Stroke, United States
https://doi.org/10.7554/eLife.81856
Share this article
Cite this article
  1. Joseph M Replogle
  2. Jessica L Bonnar
  3. Angela N Pogson
  4. Christina R Liem
  5. Nolan K Maier
  6. Yufang Ding
  7. Baylee J Russell
  8. Xingren Wang
  9. Kun Leng
  10. Alina Guna
  11. Thomas M Norman
  12. Ryan A Pak
  13. Daniel M Ramos
  14. Michael Emmerson Ward
  15. Luke A Gilbert
  16. Martin Kampmann
  17. Jonathan S Weissman
  18. Marco Jost
(2022)
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
eLife 11:e81856.
https://doi.org/10.7554/eLife.81856
  2. Download BibTeX
  3. Download .RIS

Abstract

CRISPR interference (CRISPRi) enables programmable, reversible, and titratable repression of gene expression (knockdown) in mammalian cells. Initial CRISPRi-mediated genetic screens have showcased the potential to address basic questions in cell biology, genetics, and biotechnology, but wider deployment of CRISPRi screening has been constrained by the large size of single guide RNA (sgRNA) libraries and challenges in generating cell models with consistent CRISPRi-mediated knockdown. Here, we present next-generation CRISPRi sgRNA libraries and effector expression constructs that enable strong and consistent knockdown across mammalian cell models. First, we combine empirical sgRNA selection with a dual-sgRNA library design to generate an ultra-compact (1-3 elements per gene), highly active CRISPRi sgRNA library. Next, we compare CRISPRi effectors to show that the recently published Zim3-dCas9 provides an excellent balance between strong on-target knockdown and minimal nonspecific effects on cell growth or the transcriptome. Finally, we engineer a suite of cell lines with stable expression of Zim3-dCas9 and robust on-target knockdown. Our results and publicly available reagents establish best practices for CRISPRi genetic screening.

Data availability

Sequencing data are available on NCBI GEO under accession number GSE205310 (Perturb-seq) and GSE205147 (bulk RNA-seq). sgRNA counts from CRISPRi screens are included as supplemental tables. All data generated or analyzed during this study are included in the manuscript and supporting files.

The following data sets were generated

Article and author information

Author details

  1. Joseph M Replogle

    Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States
    Competing interests
    Joseph M Replogle, consults for Maze Therapeutics and Waypoint Bio.

  2. Jessica L Bonnar

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.

  3. Angela N Pogson

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.

  4. Christina R Liem

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  5. Nolan K Maier

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-6103-6726

  6. Yufang Ding

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  7. Baylee J Russell

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  8. Xingren Wang

    Department of Microbiology, Harvard Medical School, Boston, United States
    Competing interests
    No competing interests declared.

  9. Kun Leng

    Medical Scientist Training Program, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  10. Alina Guna

    Whitehead Institute for Biomedical Research, Cambridge, United States
    Competing interests
    No competing interests declared.

  11. Thomas M Norman

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Thomas M Norman, consults for Maze Therapeutics. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq..

  12. Ryan A Pak

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    No competing interests declared.

  13. Daniel M Ramos

    Center for Alzheimer's Disease and Related Dementias, National Institutes of Health, Bethesda, United States
    Competing interests
    No competing interests declared.

  14. Michael Emmerson Ward

    National Institute of Neurological Disorders and Stroke, Bethesda, United States
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5296-8051

  15. Luke A Gilbert

    Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, United States
    Competing interests
    Luke A Gilbert, declares outside interest in Chroma Medicine. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..

  16. Martin Kampmann

    Institute for Neurodegenerative Diseases, University of California, San Francisco, San Francisco, United States
    Competing interests
    Martin Kampmann, serves on the Scientific Advisory Boards of Engine Biosciences, Casma Therapeutics, Cajal Neuroscience, and Alector, and is an advisor to Modulo Bio and Recursion Therapeutics. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-3819-7019

  17. Jonathan S Weissman

    Whitehead Institute for Biomedical Research, Cambridge, United States
    For correspondence
    weissman@wi.mit.edu
    Competing interests
    Jonathan S Weissman, declares outside interest in 5 AM Venture, Amgen, Chroma Medicine, KSQ Therapeutics, Maze Therapeutics, Tenaya Therapeutics, Tessera Therapeutics, and Third Rock Ventures. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq. LAG, MK, and JSW are inventors on US Patent 11,254,933 related to CRISPRi/a screening..

  18. Marco Jost

    Department of Microbiology, Harvard Medical School, Boston, United States
    For correspondence
    marco_jost@hms.harvard.edu
    Competing interests
    Marco Jost, consults for Maze Therapeutics and Gate Bioscience. The Regents of the University of California with TMN, MJ, LAG, and JSW as inventors have filed patent applications related to CRISPRi/a screening and Perturb-seq..
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1369-4908

Funding

National Institutes of Health (R00GM130964)

  • Marco Jost

National Institutes of Health (T32AI132120)

  • Baylee J Russell

Human Frontier Science Program (2019L/LT000858)

  • Alina Guna

Chan Zuckerberg Initiative (Ben Barres Early Career Acceleration Award)

  • Martin Kampmann

Howard Hughes Medical Institute (Investigator)

  • Jonathan S Weissman

National Institutes of Health (RM1HG009490-01)

  • Jonathan S Weissman

Springer Nature Global Grant for Gut Health (1772808)

  • Marco Jost

Charles H. Hood Foundation (Child Health Research Award)

  • Marco Jost

Defense Advanced Research Projects Agency (HR0011-19-2-0007)

  • Jonathan S Weissman

Ludwig Center for Molecular Oncology (NA)

  • Jonathan S Weissman

Chan Zuckerberg Initiative (NA)

  • Jonathan S Weissman

National Institutes of Health (F31NS115380)

  • Joseph M Replogle

National Institutes of Health (F30AG066418)

  • Kun Leng

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.

Metrics

  • 20,288
    views
  • 1,920
    downloads
  • 58
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Joseph M Replogle
  2. Jessica L Bonnar
  3. Angela N Pogson
  4. Christina R Liem
  5. Nolan K Maier
  6. Yufang Ding
  7. Baylee J Russell
  8. Xingren Wang
  9. Kun Leng
  10. Alina Guna
  11. Thomas M Norman
  12. Ryan A Pak
  13. Daniel M Ramos
  14. Michael Emmerson Ward
  15. Luke A Gilbert
  16. Martin Kampmann
  17. Jonathan S Weissman
  18. Marco Jost
(2022)
Maximizing CRISPRi efficacy and accessibility with dual-sgRNA libraries and optimal effectors
eLife 11:e81856.
https://doi.org/10.7554/eLife.81856

Share this article

https://doi.org/10.7554/eLife.81856

Categories and tags

Research organism

Further reading

    1. Computational and Systems Biology
    2. Genetics and Genomics

    Discovering root causal genes with high-throughput perturbations

    Eric V Strobl, Eric Gamazon
    Research Article

    Root causal gene expression levels – or root causal genes for short – correspond to the initial changes to gene expression that generate patient symptoms as a downstream effect. Identifying root causal genes is critical towards developing treatments that modify disease near its onset, but no existing algorithms attempt to identify root causal genes from data. RNA-sequencing (RNA-seq) data introduces challenges such as measurement error, high dimensionality and non-linearity that compromise accurate estimation of root causal effects even with state-of-the-art approaches. We therefore instead leverage Perturb-seq, or high-throughput perturbations with single-cell RNA-seq readout, to learn the causal order between the genes. We then transfer the causal order to bulk RNA-seq and identify root causal genes specific to a given patient for the first time using a novel statistic. Experiments demonstrate large improvements in performance. Applications to macular degeneration and multiple sclerosis also reveal root causal genes that lie on known pathogenic pathways, delineate patient subgroups and implicate a newly defined omnigenic root causal model.

    1. Chromosomes and Gene Expression
    2. Genetics and Genomics

    Transcription: The plusses and minuses of DNA torsion

    Steven Henikoff, David L Levens
    Insight

    A new method for mapping torsion provides insights into the ways that the genome responds to the torsion generated by RNA polymerase II.

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease

    Improved base editing and functional screening in Leishmania via co-expression of the AsCas12a ultra variant, a T7 RNA polymerase, and a cytosine base editor

    Nicole Herrmann May, Anh Cao ... Tom Beneke
    Research Advance

    The ability to analyze the function of all genes in a genome is highly desirable, yet challenging in Leishmania due to a repetitive genome, limited DNA repair mechanisms, and lack of RNA interference in most species. While our introduction of a cytosine base editor (CBE) demonstrated potential to overcome these limitations (Engstler and Beneke, 2023), challenges remained, including low transfection efficiency, variable editing rates across species, parasite growth effects, and competition between deleterious and non-deleterious mutations. Here, we present an optimized approach addressing these issues. We identified a T7 RNAP promoter variant ensuring high editing rates across Leishmania species without compromising growth. A revised CBE single-guide RNAs (sgRNAs) scoring system was developed to prioritize STOP codon generation. Additionally, a triple-expression construct was created for stable integration of CBE sgRNA expression cassettes into a Leishmania safe harbor locus using AsCas12a ultra-mediated DNA double-strand breaks, increasing transfection efficiency by ~400-fold to 1 transfectant per 70 transfected cells. Using this improved system for a small-scale proof-of-principle pooled screen, we successfully confirmed the essential and fitness-associated functions of CK1.2, CRK2, CRK3, AUK1/AIRK, TOR1, IFT88, IFT139, IFT140, and RAB5A in Leishmania mexicana, demonstrating a significant improvement over our previous method. Lastly, we show the utility of co-expressing AsCas12a ultra, T7 RNAP, and CBE for hybrid CRISPR gene replacement and base editing within the same cell line. Overall, these improvements will broaden the range of possible gene editing applications in Leishmania species and will enable a variety of loss-of-function screens in the near future.